Agenus Approaches Stock-Propelling Events

About: Agenus Inc. (AGEN)
by: William Meyers
This article is exclusive for subscribers.
William Meyers
Long Only, Tech, Biotech, Research Analyst

Balstilimab is nearing submission to FDA for commercial approval.

Agenus has a remarkably broad pipeline that is coming to fruition.

Several events in the next 12 months could propel the stock higher.

Agenus (AGEN) is a commercial stage pharmaceutical company because of its royalties from QS-21, which is a component of Shingrix. It acts more like a clinical-stage company, however, because it pre-spent the Shingrix